Loxagen is developing first-in-class therapeutics for diseases with strong unmet needs. Our team is comprised of experienced industry personnel who have taken multiple drugs to the clinic and world-renowned clinicians. Our lead is the first oral anti-thrombotic that prevents clotting without risk of bleeding. Our secondary program is the first oral therapy for Type 1 Diabetes.
The team has led 6 IND submissions, 3 New Drug Applications, and has executed over $4B in prior pharma partnerships
First gen ALOX12 inhibitor, validated in Phase 2 trials with outstanding safety and efficacy data
A raise of $15M completes Phase 1 A/B for HIT. An additional $15M completes Phase 2 for the first oral treatment for HIT
Targeting a $4B exit on a $30M investment.
CEO/Co-founder
COO
CMO
CFO
EVP, Clinical Ops
Professor, University of Michigan
Director, Cardiovascular Research Network. Leading authority on platelet biology
Professor, UC Santa Cruz
30 years of LOX expertise
